SBR00024
Trimethoprim
Ready Made Solution, 25 mg/mL in DMSO
Synonym(s):
Trimethoprim
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C14H18N4O3
Molecular Weight:
290.32
UNSPSC Code:
51285203
NACRES:
NA.76
biological source
synthetic
Assay
≥98% (HPLC)
form
liquid
ready-to-use solution
concentration
25 mg/mL in DMSO
color
colorless to faint yellow
antibiotic activity spectrum
Gram-negative bacteria
Gram-positive bacteria
mycobacteria
Mode of action
DNA synthesis | interferes
enzyme | inhibits
storage temp.
−20°C
InChI
1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18
InChI key
IEDVJHCEMCRBQM-UHFFFAOYSA-N
Related Categories
General description
Trimethoprim, an aminopyrimidine antibiotic belonging to the methoxybenzenes group, exhibits activity against a broad spectrum of both gram-negative and gram-positive aerobic bacteria. As a synthetic derivative of pyrimidine, it plays a multifaceted role as an inhibitor, xenobiotic, and allergen, featuring antibacterial, diuretic, and antiprotozoal properties. Trimethoprim selectively targets dihydrofolate reductase (DHFR), diminishing the levels of tetrahydrofolate that supply one-carbon units crucial for biosynthesis processes, including nucleotides, proteins, and panthotenate, especially in prokaryotic microorganisms.
Additionally, it is frequently employed in combination with sulfamethoxazole (sc-208405) to effectively inhibit the growth of Staphylococcus aureus, functioning as a dihydrofolate reductase inhibitor. This versatile compound finds applications in metabolomics, cell biology, and biochemical research.
Additionally, it is frequently employed in combination with sulfamethoxazole (sc-208405) to effectively inhibit the growth of Staphylococcus aureus, functioning as a dihydrofolate reductase inhibitor. This versatile compound finds applications in metabolomics, cell biology, and biochemical research.
Application
Trimethoprim is used at a final concentration of ~4μg/mL for antibacterial activty.
Biochem/physiol Actions
Mode of Action: Trimethoprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), interfering with the conversion of dihydrofolate (DHF) to tetrahydrofolate (THF). THF is an essential precursor in the thymidine synthesis pathway, interference with this pathway inhibits bacterial DNA synthesis. Trimethoprim′s affinity for bacterial DHFR is several thousand times greater than its affinity for human DHFR.
Activity Spectrum: Effective against Gram-negative bacteria, Gram-positive bacteria, and mycobacteria
Some of the pathogens that trimethoprim can be effective against include:
Activity Spectrum: Effective against Gram-negative bacteria, Gram-positive bacteria, and mycobacteria
Some of the pathogens that trimethoprim can be effective against include:
- Escherichia coli (E. coli)
- Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus or MRSA)
- Streptococcus pneumoniae
- Haemophilus influenzae
- Enterococcus faecalis
- Klebsiella species
- Proteus species
Features and Benefits
- High-quality antibiotic suitable for multiple research applications
- Ideal for Cell Biology, Metabolomics, and Biochemical research.
Other Notes
For additional information on our range of Biochemicals, please complete this form.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
188.6 °F
Flash Point(C)
87 °C
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The binding of trimethoprim to bacterial dihydrofolate reductase.
D J Baker et al.
FEBS letters, 126(1), 49-52 (1981-04-06)
Stephen Hawser et al.
Biochemical pharmacology, 71(7), 941-948 (2005-12-20)
Although only a few DHFR inhibitors have progressed as antibiotics to the market there is much renewed interest in the discovery and development of new generation DHFR inhibitors as antibacterial agents. This article describes the success in exploiting DHFR as
R N Brogden et al.
Drugs, 23(6), 405-430 (1982-06-01)
Trimethoprim, which has been widely available for several years in combination with sulphamethoxazole as co-trimoxazole, is now available for use alone in the treatment of acute uncomplicated urinary tract infections. Trimethoprim, which is active against a wide range of Gram-positive
Mahamadou A Thera et al.
The Journal of infectious diseases, 192(10), 1823-1829 (2005-10-20)
Trimethoprim-sulfamethoxazole (TS) prophylaxis is recommended for persons living with human immunodeficiency virus infection and acquired immunodeficiency syndrome in Africa. TS and the antimalarial combination sulfadoxine-pyrimethamine (SP) share mechanisms of action and resistance patterns, and concerns about the impact of TS
A Binelli et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 150(3), 329-336 (2009-06-02)
A battery of eight biomarkers was applied in the freshwater mussel Dreissena polymorpha to evaluate potential sub-lethal effects of the antimicrobial trimethoprim (TMP, 5-[3,4,5-trimethoxybenzyl]pyrimidine-2,4-diamine). Mussels were exposed for 96 h to increasing concentrations (1, 3, 10 nM) of TMP in
Articles
Cancer research innovations address the complexity of the disease, providing advanced technologies for varied applications.
Biofiles reviews innovative technologies for cancer research, reflecting the complexity of the disease.
本期生物档案回顾了我们的一些最新和最具创新性的技术及其在癌症研究中的具体应用。在准备本期生物档案时，有人指出癌症极为复杂，要确定一个与其他主题完全无关的主题极为困难。。
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service